These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28412043)

  • 1. Assessment of high-priced systemic antifungal prescriptions.
    Poulat C; Nivoix Y; Launoy A; Lutun P; Bachellier P; Rohr S; Woehl ML; Levêque D; Bru V; Herbrecht R; Gourieux B
    Med Mal Infect; 2017 Oct; 47(6):382-388. PubMed ID: 28412043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to recommendations for the use of antifungal agents in a tertiary care hospital.
    Nivoix Y; Launoy A; Lutun P; Moulin JC; Phai Pang KA; Fornecker LM; Wolf M; Levêque D; Letscher-Bru V; Beretz L; Ubeaud-Sequier G; Herbrecht R
    J Antimicrob Chemother; 2012 Oct; 67(10):2506-13. PubMed ID: 22778159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.
    Heimann SM; Vehreschild MJ; Cornely OA; Franke B; von Bergwelt-Baildon M; Wisplinghoff H; Kron F; Scheid C; Vehreschild JJ
    Eur J Haematol; 2015 Jun; 94(6):526-31. PubMed ID: 25310918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of antifungal agents in pediatric and adult high-risk areas.
    Ramírez E; García-Rodríguez J; Borobia AM; Ortega JM; Lei S; Barrios-Fernández A; Sánchez M; Carcas AJ; Herrero A; de la Puente JM; Frías J
    Eur J Clin Microbiol Infect Dis; 2012 Mar; 31(3):337-47. PubMed ID: 21720921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
    Sohn HS; Lee TJ; Kim J; Kim D
    Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections.
    Masterton RG; Casamayor M; Musingarimi P; van Engen A; Zinck R; Odufowora-Sita O; Odeyemi IA
    J Med Econ; 2013 Nov; 16(11):1344-56. PubMed ID: 24003830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Aspergillus pleural empyema with combined systemic and intrapleural antifungal therapy in a pediatric patient: Case report.
    Almuhareb A; Habib Z
    J Infect Public Health; 2018; 11(2):280-282. PubMed ID: 28545901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Update on therapy of invasive mycoses in hematology and oncology].
    Maschmeyer G; Haas A; Böhme A
    Dtsch Med Wochenschr; 2005 Jun; 130(22):1381-4. PubMed ID: 15915381
    [No Abstract]   [Full Text] [Related]  

  • 13. Airway Obstruction Due to Invasive Tracheobronchial Aspergillosis.
    Zheng X; Shao J; Xu J
    Am J Med Sci; 2016 Aug; 352(2):218. PubMed ID: 27524222
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses.
    Mistro S; Rosa L; Gomes B; Miranda L; Badaró R
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):465-73. PubMed ID: 27322156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial.
    Oyake T; Kowata S; Murai K; Ito S; Akagi T; Kubo K; Sawada K; Ishida Y
    Eur J Haematol; 2016 Jun; 96(6):602-9. PubMed ID: 26216048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
    Cesaro S; Toffolutti T; Messina C; Calore E; Alaggio R; Cusinato R; Pillon M; Zanesco L
    Eur J Haematol; 2004 Jul; 73(1):50-5. PubMed ID: 15182338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
    Salavert M; Jarque I
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative analysis of micafungin and caspofungin for empirical antifungal therapy in antibiotic-unresponsive febrile patients with hematologic malignancies.
    Seko T; Usami E; Kimura M; Nakao T; Matsuoka T; Yoshimura T; Kanamori N; Tachi T; Teramachi H
    Pharmazie; 2016 Aug; 71(8):484-488. PubMed ID: 29442037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
    Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
    Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple antifungal therapy for severe systemic candidiasis allowed performance of allogeneic stem cell transplantation.
    Gahn B; Schub N; Repp R; Gramatzki M
    Eur J Med Res; 2007 Aug; 12(8):337-40. PubMed ID: 17933709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.